Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report January-March 2020

January-March 2020 · Net sales were 419.9 MSEK (299.3), an increase of 40.3% from the equivalent quarter in 2019. Organic growth was 11.8% for the period. · Operating income increased to 56.3 MSEK (39.5), an operating margin of 13.4% (13.2). · The acquired business Hotbath contributed 83.8 MSEK to net sales and 16.0 MSEK to operating profit after amortisation of customer relationships. · Earnings per share were 3.00 SEK (2.28), an increase of 31.6% from the equivalent period in 2019. · Cash flow after investments was 23,9 MSEK (-1.0). Significant events during and after

TAT introduces “Amazing Thailand Safety and Health Administration: SHA” certification

The Tourism Authority of Thailand (TAT), in collaboration with the public and private sector partners, is introducing an “Amazing Thailand Safety and Health Administration: SHA” certification aimed at elevating the country’s tourism industry standards and developing confidence among international and domestic tourists.   The project is part of TAT’s efforts to mitigate the impacts of the Coronavirus Disease 2019 (COVID-19) crisis and accelerate recovery in the travel and tourism sector. The Amazing Thailand SHA certification is to prepare Thai tourism operators to be ready

Interim report

January 1 – March 31, 2020The first quarter in figures · Net sales amounted to TSEK 2,496 (2,368). · The loss after tax amounted to TSEK 8,936 (8,906). · The loss per share amounted to SEK 0.54 (0.54). · The cash flow from current operations was negative in the amount of TSEK 7,893 (8,950). · The gross margin reached 54.0% (52.6%). · Electrode sales volume increased by 8% and reached 6,562 (6,080) units. Repeat sales of electrodes to existing customers increased by 6%. Important events during the quarter · During Q1 2020 the Covid-19 pandemic broke out and the

Ulrica Messing and Per Uhlén new members of the Board of Directors at Rikshem

At the annual general meeting on May 4, 2020, Ulrica Messing and Per Uhlén were elected new members of the Board of Directors at Rikshem AB (publ). Lena Boberg, who declined re-election, left the board in conjunction with the meeting.The election of the new board members means that Rikshem's Board of Directors is expanded from six to seven regular members. Ulrica Messing Ulrica Messing was born in 1968 and has an educational background in social science. She is a former member of the Swedish parliament and has held minister positions in the Ministry of Enterprise and Innovation,

Anette Frumerie takes up post as CEO of Rikshem

As previously announced, Anette Frumerie will be the new CEO of Rikshem AB (publ). She takes up her new post today, May 5, 2020.“We are glad to welcome Anette Frumerie a little earlier than first communicated. Rikshem’s work to develop the property portfolio and increase the rate of production will now gain an additional energy boost, and the Board of Directors and employees look forward to start working together with Anette. I would also like to take the opportunity to say thank you to Per Uhlén, who in an exemplary way has lead Rikshem as acting CEO over the past six months,” says Bo

Changes in Saab’s Group Management

Christian Luiga has been appointed as the new CFO and a deputy CEO of Saab. Christian Luiga will start in the role no later than September 16, 2020. The Board of Directors has also appointed Anders Carp as a new deputy CEO, in addition to his current role as head of Saab's business area Surveillance. Anders Carp will start in his additional role from May 5[th ]2020.Christian Luiga recently completed the role of acting CEO of the telecommunications company Telia. He was previously CFO at Telia for several years. “In addition to being responsible for the company’s financial position,

SAS SIGNS SEK 3.3 BILLION REVOLVING CREDIT FACILITY AGREEMENT

SAS AB (publ) (“SAS”) has signed a SEK 3.3 billion three-year revolving credit facility agreement, 90% guaranteed by the Swedish and Danish states.Since the announcements from the Scandinavian governments on credit guarantees to airlines, SAS has worked with four Nordic banks as well as respective government agencies to clarify the criteria and terms for the guarantees. The guaranteed debt package, which has been approved by the European Commission, was implemented in the context of the COVID-19 crisis and is intended to support the airline’s liquidity and prepare for the recovery of its

Moberg Pharma’s Interim report for July 2019 - March 2020 to be published on May 12 - Invitation to teleconference

STOCKHOLM, May 5[th], 2020 - On May 12[th], 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - March 2020. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.The teleconference will be hosted by Moberg Pharmas’s CEO Anna Ljung and VP Finance Mark Beveridge. The presentation will be held in English. Date:             May 12[th], 2020Time:             3:00 pm (CET) To participate in the conference, please dial in on any number below before the start of the call:

Elos Medtech Interim Report January 1 - March 31, 2020

A STABLE START TO THE YEAR IN AN UNCERTAIN ENVIRONMENT January–March 2020• Net sales for the first quarter totalled SEK 158.9 (189.9) million, a decrease of 16.3 percent on the same period the year before. After currency translation, the decrease was -18.4 percent.• In the first quarter of 2019, inventory of finished products worth SEK 13.3 million was sold to Brüel & Kjær. Excluding this sale, net sales for the period decreased by 10 percent.• The operating profit was SEK 11.9 (21.4) million, which represents an operating margin of 7.5 (11.3) percent.• Profit after net financial

Global Gaming 555 AB – Quarterly report – January-March 2020

First Quarter, January - March 2020 · Revenue for the period amounted to SEK 57.8 (162.1) million. · Operating profit was SEK -0.4 (-43.3) million. · Profit after tax for the period was SEK -0.4 (-41.5) million, or SEK 0.00 (-1.02) per share. · Cash flow from operations for the period amounted to SEK -14.1 (-41.1) mkr. Other significant events during the quarter · The Administrative Court of Appeal gave a review permit for the appealed licence revocation. · The Swedish Gaming Authority rejected the request to add ninjacasino.se on Viral Interactive Limited’s licence.

Interim report January – March 2020

First quarter 2020 • Net sales for the first quarter decreased by 1% and amounted to SEK 3,445m (3,469).• Organic growth was -2% (-1).• Operating profit was SEK 134m (260), corresponding to an operating margin of 3.9% (7.5).• Changes in exchange rates negatively impacted operating profit by SEK 35m.• Profit after tax amounted to SEK 88m (183), corresponding to earnings per share after dilution of SEK 0.52 (1.09).• Operating cash flow amounted to SEK 212m (241).• The Dividend proposal was withdrawn by the Board of Directors.Comments from the President and CEO In March we

Polygon AB (publ) - Interim report 1 January - 31 March 2020

Great start to the year despite the corona outbreak.FIRST QUARTER 2020 · Sales grew 17.0% to EUR 187.1 million, organic growth amounted to 9.7% and acquired growth contributed 7.7%. · Adjusted EBITA amounted to EUR 12.4 million, an increase of 24% compared to last year. · Operating profit amounted to EUR 10.5 million (8.1). · In January, Polygon closed the acquisition of Saneringsfirman Hedbergs AB in Sweden. · In March, Polygon acquired the remaining shares of Polygon A/S in Denmark. · For the first quarter 2020, the impact of the Covid-19 outbreak has been limited for

Updates to ESL’s 2020 schedule for esports Master properties

STOCKHOLM, May 5th 2020 — Modern Times Group MTG AB’s (MTG) portfolio company ESL’s has decided to make further changes to its schedule for esports Master properties.As a consequence of the ongoing novel Coronavirus pandemic, MTG’s portfolio company ESL has decided to make further changes to its esports Master properties event schedule. This is done to ensure business continuity and continued delivery of esports entertainment in a responsible way, while taking into account current limitations and restrictions on a country per country basis. The file attached to this announcement

K-Fast Holding AB: Interim report January-March 2020

Financial ratios for the period 1 January - 31 March 2020 (corresponding period in the preceding year) · Rental income: SEK 47.8 million (33.0) · Profit from property management: SEK 15.5 million (11.1) · Profit after tax for the period: SEK 92.3 million (43.4) · Net investments in investment properties: SEK 509.2 million (137.5) · Investment properties: SEK 5,039.5 million (3,203.0) · Long-term net asset value (NAV): SEK 2,668.2 million (1,275.1) · Number of apartments under management: 1,789 (1,240) · Number of apartments under construction: 963 (649) · Number

SaltX Technology Holding AB (publ) Interim report 1 2020

Interim report 1 2020Financial eventsFirst quarter -Net sales totaled to MSEK 0.1 (-1.7) -Operating profit/loss (EBIT) amounted to MSEK -9.2 (-20.1) -Cash flow from operating activities amounted to MSEK -9.1 (-25.1) -Earnings per share before and after dilution were MSEK -0.12 (-0.29)   Significant events  First quarter  -SaltX Chinese partners initiate construction of a pilot plant -Uncertainty about the effect of covid-19   Interim report 1 can be downloaded at http://saltxtechnology.com under the Investor tab .

Clevegen manufacturing agreement

Faron Pharmaceuticals Oy("Faron" or the "Company")  Faron contracts with AGC Biologics in commercial scale Clevegen manufacturing agreement  Company announcement, 05 May 2020 at 9.00 AM (EEST)Inside informationTURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that global contract development and manufacturing organisation AGC Biologics has been selected to be the commercial scale manufacturer of Clevegen, Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive

Notice of Ponsse’s Annual General Meeting

Ponsse Plc’s (“Ponsse”) shareholders are hereby invited to attend the Annual General Meeting to be held on Wednesday 27 May 2020, at 10:00 a.m. EET, in the auditorium of the company’s customer service centre at Ponssentie 22, FI-74200 Vieremä, Finland, using exceptional arrangements due to the coronavirus situation. Reception of those registered for the meeting and the distribution of ballots will begin at 9:30 a.m. EET.Ponsse takes the coronavirus situation seriously and has decided to organise the Annual General Meeting in these exceptional circumstances so that the number of participants

Veidekke ASA: To build new residential project in Malmö

Veidekke Entreprenad has been commissioned by Veidekke Eiendom to build the first stage of Atmosfären, a new residential project in Malmö. The contract has a value of SEK 142 million.The new residential area Atmosfären in Limhamns Sjöstad outside Malmö will comprise 90 units of different sizes. Since sales start in June of last year, the project has attracted great interest, and Veidekke Eiendom has now commissioned Veidekke Entreprenad to build the first stage. This stage encompasses 62 residential units and an underground garage which will service both building stages. Construction will

Interim report January - March 2020

Gothenburg, May 5, 2020 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2020.Important events during the first quarter · In January, Vicore issued 243,525 shares to the warrant holders in the incentive programme LTIP 2016. · In the beginning of 2020, the phase II study with C21 in patients with systemic sclerosis (SSc) and Raynaud's phenomenon dosed its first patients. · In March, Vicore submitted a Clinical Trial Application (CTA) to the UK regulatory agency MHRA, for a phase II study with C21 in patients with IPF. The study has been re-

Interim report January-March 2020

KICK-OFF FOR A NEW ORGANIZATION  January-March 2020 · Order bookings amounted to SEK 2,975 million (1,177) and the order backlog was SEK 10,576 million (5,973) · Income amounted to SEK 1,814 million (1,480) · The operating loss was SEK 149 million (profit 18), of which non-recurring expenses amounted to SEK 135 million · At the end of the period, available cash and cash equivalents totaled SEK 587 million · Cash flow from operating activities amounted to an outflow of SEK 233 million (262) · Cash flow for the period amounted to an outflow of SEK 50 million, of which

GlobalConnect appoints Henrik Schibler as new Group CFO

Northern Europe’s leading digital infrastructure provider, GlobalConnect appoints Henrik Schibler as its new Group Chief Financial Officer (CFO). He is currently the European Chief Operating Officer at ISS and will assume his new position on August 10, 2020.“I couldn’t be happier welcoming Henrik to our team. He holds many of the crucial qualities I look for in a strategic and business minded CFO. As GlobalConnect/IP-Only continues to grow with customer centric products and services, Henrik’s contributions will play a key role to our success as we continue our expansion across Northern

Vicore Pharma receives regulatory approval to start phase II clinical trial with VP01 (C21) in patients with IPF

Gothenburg, May 5, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces the approval by the UK regulatory agency (MHRA[1]) of the clinical trial application (CTA) for a phase II study with its proprietary compound VP01 (C21) in patients with IPF (idiopathic pulmonary fibrosis).Approximately five weeks after submitting the CTA, Vicore Pharma has received approval from the MHRA to start the study. In addition to the MHRA approval, a favourable opinion from the ethics committee is also required

SynAct presents initial data from the first part of the Phase II study within RA and gives an update on its progression

· The first of two tested doses (50 mg) identified to be safe and well-tolerated. · The blinded review revealed that patients in the study form two groups based on changes in their clinical disease activity index (CDAI). · Based on the safe and well-tolerated first dose (50 mg) the company now initiates the next dose level (100 mg). SynAct Pharma AB ("SynAct") hereby announces that the company, based on a blinded review of data from the company´s ongoing Phase II study entitled ”A double-blind, multi-center, two-part, randomized, placebo-controlled study of the safety, tolerability,

Interim Report January–March 2020

Quarter January–March 2020 · Net sales increased by 7 percent to SEK 1,658 (1,544) million · EBITA increased by 65 percent to SEK 62 (37) million · Profit after tax increased to SEK 14 (-1) million · Earnings per ordinary share amounted to SEK -0.02 (-0.21) Events after the reporting period · On 16 April, Volati announced preliminary results for Q1 2020 and issued an update on the impact of the Coronavirus. · On 16 April, Volati is postponing the AGM from 6 May to 25 June 2020. COMMENTS FROM THE CEO A strong first quarter Volati delivered a significantly

There are no items matching the current filter
There are no more items matching the current filter
Back to top